SHORT COMMUNICATION

Maladaptation of the maternal cardiovascular system as a cause of fetal growth restriction: Study rationale and design

Aleksandra Ciepłucha1Mariola Ropacka-Lesiak2Sylwia Sławek-Szmyt1Ludwina Szczepaniak-Chicheł3Agnieszka Bartczak-Rutkowska1Natalia Misan2Andrzej Tykarski3Maciej Lesiak1Katarzyna Kawka-Paciorkowska2
11st Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland
2Department of Perinatology and Gynecology, Poznan University of Medical Sciences, Poznań, Poland
3Department of Hypertensiology, Poznan University of Medical Sciences, Poznań, Poland

Correspondence to:

Aleksandra Ciepłucha, MD, PhD,

1st Department of Cardiology, Poznan University of Medical Sciences,

Długa 1/2, 61–848 Poznań, Poland,

phone: +48 618 549 146,

e-mail: aleksandra.cieplucha@skpp.edu.pl

Copyright by the Author(s), 2022

DOI: 10.33963/KP.a2022.0287

Received: November 11, 2022

Accepted: December 22, 2022

Early publication date: December 22, 2022

Introduction

The mortality rate among pregnant women is low, nevertheless, cardiovascular diseases (CVD) are the leading cause of death (approximately 30%) in this particular population [1]. The clinical presentation of CVD might be miscellaneous as symptoms are commonly atypical and attributed to pregnancy itself [2, 3]. Pregnancy acts as a physiological stress test, thus the development of certain obstetric complications might be evidence of abnormal adaptation of the cardiovascular system to this condition. According to the latest research, particularly preeclampsia and impaired fetal growth may result from such a maladaptive process [3]. The importance of these associations has been raised by the current guidelines, which now recommend considering a pregnancy history as part of the routine evaluation of cardiovascular risk in women [2].

A condition called fetal growth failure includes both small gestational age (SGA) and fetal growth restriction (FGR) [4]. SGA refers to pregnancies with a constitutionally determined fetal weight between the third and tenth percentile accompanied by a normal vascular blood flow on ultrasound assessment and a good overall prognosis. In contrast to that, FGR is one of the most common adverse outcomes during pregnancy reported in up to 10% of cases, and a leading cause of infant morbidity and mortality [4, 5]. By definition, in FGR the fetus does not achieve its genetic potential with the programmed birth weight due to pathological reasons [4, 5]. FGR is classified based on gestational age at prenatal ultrasound diagnosis as early-onset diagnosed before 32 weeks of gestation and late-onset diagnosed at or after 32 weeks of gestation. The etiology of FGR remains unclear and can be caused by maternal factors (hypertension, diabetes, cardiopulmonary disease, anemia, malnutrition, smoking, and drug use), fetal causes (genetic factors, congenital malformations, fetal infection, and multiple pregnancies), and placental abnormalities (placental insufficiency, placental infarction, and placental mosaicism) [3, 5].

Having said that, it is important to thoroughly determine the cardiovascular profile of pregnant women with impaired fetal growth. Comprehensive profiling could be useful in identifying patients at high risk of both FGR development during pregnancy as well as subsequent cardiovascular complications in the mother.

Methods

This interdisciplinary project is a single-center prospective study conducted in the 1st Department of Cardiology and the Department of Perinatology and Gynecology at the Poznań University of Medical Sciences, Poznań, Poland.

The research objectives are to establish the frequency of abnormalities in the maternal cardiovascular system and their correlation with fetal growth impairment.

Patients will be enrolled in the study in two stages. In the first stage, 150 patients between 24 and 38 weeks of pregnancy complicated by impaired fetal growth will be enrolled. The diagnosis of FGR will be made based on the current Delphi criteria [6]. The control group will include 50 patients between weeks 24 and 41 of pregnancy with a physiologically normal pregnancy, who will give birth to appropriate for gestational age (AGA) children.

In the second stage, patients from the study group will be divided into 3 subgroups depending on the final diagnosis: Group 1: SGA; Group 2: FGR without pregnancy-induced hypertension; Group 3: FGR with pregnancy-induced hypertension (synonymous with the diagnosis of pre-eclampsia) (Figure 1).

Figure 1. The study flow chart showing allocation of the enrolled pregnant women with regard to the type of the diagnosed fetal growth impairment
Abbreviations: hbd, week of gestation; FGR, fetal growth restriction; SGA, small gestational age

The exclusion criteria are 1) multiple pregnancy, 2) fetal defects, 3) infections from the TORCH group, 4) a known significant cardiovascular disease in the mother, 5) pregnancy diabetes, 6) antiphospholipid syndrome, thrombophilia, and other recognized disorders of the coagulation system, 7) significant kidney disease with GFR <60/min before pregnancy, 8) significant autoimmune diseases of connective tissues (systemic lupus, antiphospholipid syndrome, etc.) 9) placental defects, 10) nicotine addiction, alcohol addiction, or other psychoactive substance addiction (regular substance intake at least twice a week three months before and/or during pregnancy).

The study protocol includes:

  1. Detailed physical examination and collection of relevant clinical data.
  2. Ultrasound assessment of the fetus, including fetal biometric assessment and doppler measurements.
  3. Basic laboratory tests including the most commonly used cardiovascular parameters (complete blood count, creatinine, sodium, potassium, alanine aminotransferase, aspartate aminotransferase, total bilirubin, C-reactive protein, total cholesterol, HDL-cholesterol, LDL cholesterol, triglycerides, Prothrombin Time, PT/INR, Activated Partial Thromboplastin Time (aPTT), D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP), and cardiac troponin I.
  4. Biochemical tests of advanced markers of cardiovascular dysfunction: lipocalin-2, retinol-binding protein 4, adiponectin, fibroblast growth factor 19 and 21, tissue plasminogen activator, angiotensin A and vasoconstriction inhibiting factor.
  5. Echocardiographic examination of the mother (basic assessment of anatomy, systolic and diastolic function with advanced evaluation based on the tissue Doppler technique).
  6. Routine electrocardiographic parameters at rest.
  7. Functional assessment of the arterial bed, including examination of central pressure (central systolic and diastolic pressure in the aorta), and the parameters of arterial stiffness (pulse wave velocity [PWV]) by applanation tonometry.
  8. Assessment of the daily profile of peripheral arterial pressure (ambulatory 24-hour monitoring of blood pressure ABPM).
  9. The course and mode of delivery, the condition of the neonate and the mother.
  10. Re-assessments of maternal echocardiographic parameters after puerperium (612 months after delivery).

The study design was approved by the local ethics committee (EC approval number 100/22 dated February 17, 2022). All patients gave informed written consent to participate in the study.

Statistical analysis

For continuous variables and ordinal variables, median values with minimal and maximal ranges were reported. Categorical data were reported as the number and percentage of patients. The statistics were calculated with STATISTICA 13 software (TIBCO Software, Palo Alto, CA, US)

Preliminary results and discussion

During the first six months of the study duration, 25 pregnant women (median age, 34 years; range 2641 years) were recruited to the study. The majority of them (15 [60%]) were diagnosed with impaired fetal growth before the 32nd week of gestation. After labor, the final diagnosis of FGR was confirmed in 20 (80%) participants, whereas 5 (20%) were eventually classified as SGA. In eight patients (32%), preeclampsia complicated the course of pregnancy.

In terms of echocardiography, the dimensions of the heart chambers were within the normal range in all included patients, and so was left ventricular (LV) ejection fraction (median, 60.5%; range, 5370%). The wider spread among calculated values was observed in LV global longitudinal strain which ranged from an abnormally low value of –10.4% to normal –22.6% (median, –17.6%). The systolic function of the right ventricle (RV) was assessed by the tricuspid annular systolic myocardial velocity S’ measurement (median, 14 cm/s; range 722 cm/s). The assessment of RV global longitudinal strain turned out not to be technically feasible in the majority of our patients (16 [64%]) due to the poor-quality images.

Our preliminary results are consistent with the previous reports about the cardiovascular system in healthy pregnant women, particularly in the context of the left ventricular global strain [7, 8]. The other echocardiographic data are within the normal range. We are still expecting a biochemical profiling and vascular functional assessment to be analyzed along with the prospective data as the follow-up is scheduled 612 months after delivery.

Conclusions

Our study may provide important data on the detection, diagnosis, and management of pregnant women with a high cardiovascular risk.

Article information

Conflict of interest: None declared.

Funding: None.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

REFERENCES

  1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100): 11511210, doi: 10.1016/S0140-6736(17)32152-9, indexed in Pubmed: 28919116.
  2. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 32273337, doi: 10.1093/eurheartj/ehab484, indexed in Pubmed: 34458905.
  3. Ukah UV, Auger N. Severe maternal morbidity and risk of cardiovascular disease: Recent advances. Kardiol Pol. 2022; 80(6): 638643, doi: 10.33963/KP.a2022.0119, indexed in Pubmed: 35521721.
  4. Martins JG, Biggio JR, Abuhamad A. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction. Am J Obstet Gynecol. 2020; 223(4): B2BB17, doi: 10.1016/j.ajog.2020.05.010, indexed in Pubmed: 32407785.
  5. Figueras F, Caradeux J, Crispi F, et al. Diagnosis and surveillance of late-onset fetal growth restriction. Am J Obstet Gynecol. 2018; 218(2S): S790S802.e1, doi: 10.1016/j.ajog.2017.12.003, indexed in Pubmed: 29422212.
  6. Khalil A, Gordijn SJ, Beune IM, et al. Essential variables for reporting research studies on fetal growth restriction: a Delphi consensus. Ultrasound Obstet Gynecol. 2019; 53(5): 609614, doi: 10.1002/uog.19196, indexed in Pubmed: 30125411.
  7. Sengupta SP, Bansal M, Hofstra L, et al. Gestational changes in left ventricular myocardial contractile function: new insights from two-dimensional speckle tracking echocardiography. Int J Cardiovasc Imaging. 2017; 33(1): 6982, doi: 10.1007/s10554-016-0977-y, indexed in Pubmed: 27628530.
  8. Sławek-Szmyt S, Kawka-Paciorkowska K, Ciepłucha A, et al. Preeclampsia and fetal growth restriction as risk factors of future maternal cardiovascular disease-a review. J Clin Med. 2022; 11(20), doi: 10.3390/jcm11206048, indexed in Pubmed: 36294369.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl